Dr. Andrew Bomback uses a case vignette to illustrate the work-up of a patient who presents with secondary hypertension in order to differentiate between hypertensive urgency and hypertensive emergency and formulate appropriate interventions.
Dr. Goodman will discuss clinical concerns regarding common thrombotic issues. He will review the causes and the utility of hypercoaguable states. He will discuss the limits of diagnostic testing for idiopathic thrombosis and talk about the treatment options for this condition.
This activity reviews diagnostic and therapeutic approaches for patients with atrial arrhythmias, including supraventricular tachycardia, atrial flutter and atrial fibrillation. Faculty will discuss the safety and efficacy of catheter ablation compared with pharmacologic therapy, as well as recent data on how risk factor modification (hypertension, obesity, exercise, sleep apnea, alcohol) can be used as a means to reduce the recurrence rate for atrial fibrillation.
This talk will review the new ACC-AHA Hypertension guidelines and emphasize what’s old, what’s new, and what has changed.
This talk will emphasize new guidelines for cardiovascular disease prevention, highlighting the big three risk factors: hypertension, hyperlipidemia, and diabetes. The talk will also discuss controversies and commonalities, and offer practical tips for implementing the guidelines.
Using case studies, Dr. Watson demonstrates how to handle clinical scenarios frequently encountered in practice. Follow the case discussion to learn about optimal care and management strategies for hypertension patients.
In this activity, Dr. Anderson answers some common questions encountered by primary care physicians in the management and care of patients with heart failure. Some of the topics discussed include the use of cardiac MRI, appropriate use of biomarkers and the recommended drugs to be used in patients with heart failure.
In this Clinical Coffee Break, Dr. Tenenbaum addresses the pathophysiologic changes that occur after aortic valve repair and the most common symptoms that persist after aortic valve repair such as shortness of breath, fainting, and chest pain.
Despite significant advances in heart failure management, including pharmacotherapy and devices, treating this complex condition remains challenging. This activity discusses the differences in pathophysiology of heart failure with reduced and preserved ejection fraction and the different treatment approaches required for each condition. Novel agents under investigation that hold promise for treatment of this population are also discussed.
Heart failure (HF) affects over 5 million Americans, with 825,000 new cases occurring annually and a resultant 1,000,000 hospitalizations, which translates into an annual estimated cost of over $30 billion dollars. Implementation of the advances in management of heart failure have the potential to improve patients' quality of life, reduce the need for hospitalizations, reduce total medical costs, and prolong survival. This activity will review the current evidence-based, guideline recommended diagnosis and management of heart failure. Dr. Fonarow, a leading expert in Cardiovascular Medicine will discuss the essential roles of evidence-based heart failure medications, device therapy, patient education, and disease management.